| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.corallab.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 153.84 Cr. | |
| Earnings per share (EPS) | 37.94 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 11.35 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 382.48 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.13 | Calculated using Price: 430.60 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.36 Cr. | 3,572,600 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Coral Laboratories was founded in 1994. The company is equipped with an ultra modern manufacturing unit in the state of Gujarat, Daman & today is a force to reckon with in the pharmaceutical industry; a fact which has been endorsed by the WHO GMP certification issued by the Food & Drugs Control Administration and ISO 9001-2000 Quality certification issued by American Quality Assessors. The Company with deep basket of products is focused in hostlic human welfare and is bringing planfort to people with its Inflammatory, Bacterial, Biotic, Protein deficiencies & Skin conditions. Medicines across the nation, manufactured under the ZEST group & MOXBRO group being the most popular brands across the nation, manufactured by the company.Coral Laboratories has been following a steady growth path on the pillars of its philosophy of “Total Quality Management” & “Quality Products at Affordable Prices”. The state-of-the art manufacturing facilities meet the stringent and over changing quality requirement of the most discerning buyers. Coral has a multi location manufacturing facilities based on Baroda, Daman & Vasai for strategies convenience. The facilities carrying WHO-GMP & ISO 9001 : 2000 certification. The new manufacturing facilities under expansion to have UK – MHRA and US– FDA certification. Coral has one of the best quality control laboratory in indian pharmaceuticals industry equipped with latest and sensitive laboratory instruments. Product range of the company includes:
Achievements/ recognition:
|
||
Company Profile
Coral Laboratories was founded in 1994. The company is equipped with an ultra modern manufacturing unit in the state of Gujarat, Daman & today is a force to reckon with in the pharmaceutical industry; a fact which has been endorsed by the WHO GMP certification issued by the Food & Drugs Control Administration and ISO 9001-2000 Quality certification issued by American Quality Assessors.
The Company with deep basket of products is focused in hostlic human welfare and is bringing planfort to people with its Inflammatory, Bacterial, Biotic, Protein deficiencies & Skin conditions. Medicines across the nation, manufactured under the ZEST group & MOXBRO group being the most popular brands across the nation, manufactured by the company.Coral Laboratories has been following a steady growth path on the pillars of its philosophy of “Total Quality Management” & “Quality Products at Affordable Prices”.
The state-of-the art manufacturing facilities meet the stringent and over changing quality requirement of the most discerning buyers. Coral has a multi location manufacturing facilities based on Baroda, Daman & Vasai for strategies convenience. The facilities carrying WHO-GMP & ISO 9001 : 2000 certification. The new manufacturing facilities under expansion to have UK – MHRA and US– FDA certification.
Coral has one of the best quality control laboratory in indian pharmaceuticals industry equipped with latest and sensitive laboratory instruments.
Product range of the company includes:
Achievements/ recognition:
| 1 Day |
|
+1.53% |
| 1 Week |
|
+1.67% |
| 1 Month |
|
-11.81% |
| 3 Month |
|
+15.76% |
| 6 Month |
|
+53.63% |
| 1 Year |
|
+100.16% |
| 2 Year |
|
+125.84% |
| 5 Year |
|
-9.34% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 15.85 | 14.76 | 16.72 | 17.46 | 19.18 | 18.17 | 11.04 | 8.88 | 6.22 | |
| Return on Capital Employed (%) | 20.18 | 18.70 | 21.24 | 22.22 | 26.93 | 27.23 | 15.91 | 13.44 | 7.86 | |
| Return on Assets (%) | 12.49 | 11.25 | 13.25 | 14.40 | 15.32 | 14.77 | 9.17 | 7.40 | 5.09 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 38 | 44 | 51 | 59 | 70 | 109 | 116 | 114 | 116 | |
| Non Curr. Liab. | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | |
| Curr. Liab. | 10 | 14 | 9 | 12 | 18 | 19 | 20 | 18 | 25 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 49 | 58 | 61 | 72 | 89 | 131 | 140 | 136 | 144 | |
| Non Curr. Assets | 25 | 24 | 23 | 22 | 25 | 58 | 68 | 52 | 48 | |
| Curr. Assets | 24 | 34 | 37 | 50 | 65 | 74 | 72 | 84 | 96 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 49 | 58 | 61 | 72 | 89 | 131 | 140 | 136 | 144 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 40 | 42 | 51 | 59 | 77 | 95 | 92 | 91 | 71 | |
| Other Income | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 5 | 6 | |
| Total Income | 41 | 43 | 52 | 62 | 80 | 99 | 97 | 96 | 76 | |
| Total Expenditure | -32 | -34 | -41 | -47 | -61 | -72 | -77 | -79 | -65 | |
| PBIDT | 8 | 9 | 11 | 15 | 19 | 27 | 20 | 18 | 11 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -3 | -2 | -2 | -2 | -2 | -2 | |
| Taxation | -1 | -2 | -2 | -3 | -5 | -8 | -6 | -5 | -2 | |
| Exceptional Items | 0 | |||||||||
| PAT | 6 | 6 | 8 | 10 | 12 | 16 | 12 | 10 | 7 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | 0 | 1 | 0 | 5 | 11 | 13 | -1 | -4 | |
| Cash Fr. Inv. | 0 | 0 | 1 | 0 | -3 | -10 | -13 | 3 | -2 | |
| Cash Fr. Finan. | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -1 | 4 | |
| Net Change | 3 | 1 | 2 | 0 | 2 | 1 | -2 | 1 | -2 | |
| Cash & Cash Eqvt | 4 | 5 | 7 | 7 | 9 | 4 | 2 | 3 | 1 |
|
Mon, 19 Jul 2021
Disclosure Under Reg. 23(9) Of SEBI (LODR) Regulations 2015 Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements Regulations) 2015 we hereby submit disclosure of Related Party Transactions for the half year ended March 31 2021 in accordance with the applicable Accounting Standards. Request you to take the same on record and acknowledge. |
|
Mon, 12 Jul 2021
Shareholding for the Period Ended June 30 2021 Coral Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
|
Fri, 09 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find attached herewith Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 furnished by M/s. Link Intime India Private Limited the Registrar and Share Transfer Agent of the Company for the quarter ended June 30 2021. You are requested to take the same on record. |
| Fri, 23 Jul 2021 |
Stock Outperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Outperforming Sectoral Index in both 1 Week and 3 Month
|
Both SRS And ARS Above Zero
|
Stochastic Reversing from Oversold Zone from Below
|
NR 4
|
Equities
M.F.
Sectors